Speaker Profile

Co-Founder and CEO, BryoLogyx

Biography
Tom’s 45+ year healthcare career spans four product domains – medtech, drug/device combinations, digital health, and biotech. He is a solutions-oriented executive who started his healthcare career at American Hospital Supply Corporation (BAXTER) as a turn-around executive. He has led the commercialization of over 20 innovative products across 13 specialties or disease domains. Since leaving the multinational corporate suite, Tom has focused on building companies, taking multiple early-stage stage companies from concept to commercialization while raising capital in both the private and public markets. He presently serves as the Chairman of the Board for the Dallas-based The ReFocus Group. and He has served: as an assistant professor of surgery, Creighton University Medical School; on the boards of numerous healthcare companies. as a member of the Dean’s Advisory Council, Jacobs School of Engineering, University of California at San Diego; and as a member of the Executive Committee for AdvaMed.


Immunotherapy Showcase:
BryoLogyx

BryoLogyx Inc. is developing a new class of proprietary drugs to enhance the response rates and treatment durability of cancer immunotherapies.

Target Antigen Modulation: Improving Immunotherapy Efficacy/Durability
BryoLogyx’s bryostatin offers a highly differentiated approach to improving the efficacy/durability of immunotherapy. A strong scientific rationale, compelling pre-clinical data, and a clear clinical-based signal supports its near-term promise for tagging tumors, making them vulnerable to being destroyed by immunotherapy.

 Session Abstract – PMWC Silicon Valley


The PMWC 2020 Immunotherapy Showcase will provide a 15-minute time slot for selected immunotherapy companies to present their latest technologies and advancements to an audience of leading investors, potential clients, and partners. We will hear from companies building new cell-based immunotherapies, work in the growing area of cancer vaccines, that help understand the relevance of the tumor microenvironment, accelerate the patient selection process, or otherwise work towards overcoming to challenges related to therapeutic discovery.